Skip to content

Harm-reduction information only — not medical advice. In crisis or experiencing adverse effects, contact a healthcare professional or your local emergency services immediately.

AnabolicPlotter logo AnabolicPlotter
Search (no-JS fallback)
Anabolic Steroids/Hormones Human RCT evidence

Testosterone Cypionate

Test Cyp · TC

6.9 days
Half-life
100–600 mg
Typical dose
2×/week
Frequency
TRT ongoing / cycles 10–16 weeks
Cycle length

Standard US TRT ester with a slightly longer release tail than enanthate. Steady state ~4–5 weeks.

Key takeaways

  • The standard US TRT ester — ~8-day half-life, steady state in about 5 weeks.
  • Twice-weekly injection smooths peak-to-trough swings and reduces estradiol/hematocrit side effects vs once-weekly.
  • Aromatizes to estradiol and 5α-reduces to DHT — trough total/free T, E2, hematocrit, lipids, and PSA are the core monitoring set.
  • Complete HPTA suppression follows any non-TRT use — plan PCT before the cycle starts, not after.

Overview

What it is

Testosterone cypionate is the most prescribed injectable testosterone ester in the US, used clinically for hormone replacement therapy (TRT) and off-label as a cycle base. The cypionate ester controls the release rate: once injected into muscle, tissue esterases slowly cleave it, freeing testosterone to bind the androgen receptor and drive protein synthesis, nitrogen retention, and erythropoiesis.

Pharmacokinetics

Its roughly 8-day half-life supports once- or twice-weekly injection, with steady state reached after about 5 weeks. Twice-weekly dosing narrows the peak-to-trough swing, which reduces estradiol and hematocrit side effects compared to the same weekly total injected once.

Harm reduction

It aromatizes to estradiol and 5-alpha-reduces to DHT, so monitoring trough total/free T, estradiol, hematocrit, lipids, and PSA is central. HPTA suppression is complete and rapid, so any non-TRT use needs a structured PCT planned before the cycle starts. It is not hepatotoxic since it bypasses first-pass metabolism.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case Dose Route Frequency Duration
TRT (clinical) 75–100 mg weekly (or 150–200 mg q2wk) IM 1–2× weekly Ongoing
Performance (community) 300–600 mg weekly IM 2× weekly 10–16 weeks

Pharmacokinetic summary

Model tier
Linear Regression (sublinear dose)
Half-life
6.9 days
Cmax
964 ng/dL
Tmax
4.5 days
Bioavailability
70%
Typical dose
100–600 mg

Harm reduction

Aromatizes
Yes
DHT derivative
No
Injection frequency
2×/week
Bloodwork range
300–1000 ng/dL

Frequently asked questions

Cypionate vs enanthate — does it matter?

Barely. Cypionate is one carbon longer on the ester, giving a marginally longer tail (~8 vs ~7 days half-life). Dosing schedules and blood levels are effectively interchangeable; cypionate dominates in the US, enanthate elsewhere.

Why inject twice a week instead of once?

Splitting the weekly dose narrows the peak-to-trough swing. High peaks drive more aromatization to estradiol and larger hematocrit excursions; lower troughs avoid the end-of-week crash. Same weekly milligrams, smoother curve — the plotter shows this directly.

Do you need PCT after testosterone cypionate?

For any non-TRT use, yes. Exogenous testosterone fully suppresses the HPTA within weeks. A structured PCT (typically SERMs, sometimes hCG beforehand) restarts endogenous production after the ester clears — with an ~8-day half-life, that means waiting roughly 2–3 weeks post-last-injection before starting SERMs.

References

Related articles

Related compounds

Protocols featuring Testosterone Cypionate

Comments

Loading comments…